Free Trial

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$0.62 -0.01 (-1.32%)
Closing price 04:00 PM Eastern
Extended Trading
$0.61 -0.01 (-1.13%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRAX vs. HOOK, PHXM, ALBT, IMCC, PCSA, VIVS, ADXN, APM, BCDA, and RNAZ

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include HOOKIPA Pharma (HOOK), PHAXIAM Therapeutics (PHXM), Avalon GloboCare (ALBT), IM Cannabis (IMCC), Heatwurx (PCSA), VivoSim Labs (VIVS), Addex Therapeutics (ADXN), Aptorum Group (APM), BioCardia (BCDA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry.

Virax Biolabs Group vs. Its Competitors

Virax Biolabs Group (NASDAQ:VRAX) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Virax Biolabs Group has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, HOOKIPA Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Virax Biolabs Group has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Virax Biolabs Group's return on equity of 0.00% beat HOOKIPA Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
HOOKIPA Pharma -785.66%-120.09%-77.14%

Virax Biolabs Group has higher earnings, but lower revenue than HOOKIPA Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K269.08-$6.06MN/AN/A
HOOKIPA Pharma$9.35M1.21-$43.50M-$5.85-0.16

Virax Biolabs Group presently has a consensus price target of $3.00, suggesting a potential upside of 383.87%. HOOKIPA Pharma has a consensus price target of $4.50, suggesting a potential upside of 383.87%.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
HOOKIPA Pharma
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Virax Biolabs Group's average media sentiment score of 0.00 equaled HOOKIPA Pharma'saverage media sentiment score.

Company Overall Sentiment
Virax Biolabs Group Neutral
HOOKIPA Pharma Neutral

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Virax Biolabs Group beats HOOKIPA Pharma on 8 of the 10 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.69M$3.16B$5.79B$10.49B
Dividend YieldN/A2.36%5.61%4.57%
P/E RatioN/A21.17348.8926.87
Price / Sales269.08411.81522.55164.30
Price / CashN/A44.8326.0131.15
Price / Book0.499.8315.536.50
Net Income-$6.06M-$52.82M$3.29B$271.42M
7 Day Performance-4.05%3.47%200.87%3.69%
1 Month Performance-18.95%5.35%184.38%8.07%
1 Year Performance-74.59%13.26%325.51%29.65%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
1.6479 of 5 stars
$0.62
-1.3%
$3.00
+383.9%
-74.3%$2.69M$10K0.005
HOOK
HOOKIPA Pharma
2.4581 of 5 stars
$0.90
-3.7%
$4.50
+402.5%
-80.5%$10.92M$9.35M-0.15160Positive News
Gap Down
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58MN/A0.0049
ALBT
Avalon GloboCare
0.6623 of 5 stars
$2.70
+3.8%
N/A-12.5%$10.37M$1.33M-0.145Gap Up
IMCC
IM Cannabis
0.2882 of 5 stars
$1.96
+1.6%
N/A-6.7%$10.29M$39.44M-3.63340Gap Down
PCSA
Heatwurx
2.9791 of 5 stars
$0.20
+0.0%
$1.00
+398.8%
-85.8%$10.10MN/A-0.0920
VIVS
VivoSim Labs
0.263 of 5 stars
$3.84
-19.7%
N/AN/A$9.98M$140K-0.3820
ADXN
Addex Therapeutics
2.267 of 5 stars
$9.37
-2.6%
$30.00
+220.2%
-8.8%$9.93M$170.62K-27.5630Positive News
Upcoming Earnings
APM
Aptorum Group
0.2733 of 5 stars
$1.85
-5.6%
N/A-18.2%$9.89MN/A0.0030Analyst Upgrade
BCDA
BioCardia
3.3316 of 5 stars
$1.70
-20.9%
$25.00
+1,370.6%
-54.3%$9.86MN/A-0.9240Analyst Forecast
High Trading Volume
RNAZ
TransCode Therapeutics
2.062 of 5 stars
$11.67
+6.6%
$280.00
+2,299.3%
-99.9%$9.69MN/A0.009Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:VRAX) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners